TSO3 to Present at Bloom Burton & Co. Healthcare Investor Conference on May 2, 2016

QUEBEC CITY, April 18, 2016 /CNW Telbec/ - TSO₃ Inc. (TSX: TOS), an innovator in sterilization technology for medical devices in healthcare settings, has been invited to present at Bloom Burton & Co. Healthcare Investor Conference being held on May 2-3, 2016 at the Sheraton Centre Toronto Hotel in Toronto, Ontario.

TSO₃ management is scheduled to present on Monday, May 2, 2016 at 9:30 a.m. EDT, with one-on-one meetings held throughout the conference.

Management will discuss the company's business, commercial rollout and future planned enhancements for its STERIZONE^® VP4 Sterilizer.

The presentation will be webcast live at http://wsw.com/webcast/bloomburton/tos.to, which will be available for replay in the Investors section at www.tso3.com.

For more information about the conference or to schedule a one-on-one meeting with TSO₃ management, please contact your Bloom Burton & Co. representative.

About the STERIZONE^® VP4 low temperature sterilizer

The STERIZONE_® VP4 Sterilizer developed by TSO₃ is a dual sterilant, low temperature sterilization system that utilizes vaporized hydrogen peroxide (H₂O₂) and ozone. Its single cycle can sterilize a large number and wide range of compatible devices, thereby allowing for a cost effective and error-free sterilization process. TSO₃'s unique Dynamic Sterilant Delivery System^TM automatically adjusts the quantity of injected sterilant based on the load composition, weight and temperature. With its large 75 lb load capacity and a short cycle time, the STERIZONE^® VP4 Sterilizer can enhance throughput and lower sterilization cost. In December 2014, the STERIZONE^® VP4 Sterilizer was cleared for commercialization in the U.S.

About TSO₃

Founded in 1998, TSO₃ is committed to improving the standard of healthcare sterile reprocessing by providing breakthrough sterilization systems, related consumable supplies and accessories for heat-sensitive medical devices. TSO₃ designs products for sterile processing areas in the hospital environment that offer an advantageous replacement solution to other low-temperature sterilization processes currently used in hospitals. It also offers services related to the maintenance of sterilization equipment and compatibility testing of medical devices with such processes.

For more information about TSO₃, visit the company's web site at www.tso3.com.

The statements in this release and oral statements made by representatives of TSO₃ relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of TSO₃'s sales, business or operations) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO₃ to obtain financing on favourable terms and other risks and uncertainties. 

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful.

The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.

SOURCE TSO3 Inc.

Image with caption: "Logo: TSO3 (CNW Group/TSO3 Inc.)". Image available at: http://photos.newswire.ca/images/download/20160418_C3602_PHOTO_EN_666976.jpg

Company Contact: TSO3 Inc., R.M. (Ric) Rumble, President and CEO, Tel: [phone], Email: [email protected]; TSO3 Inc., Glen Kayll, CFO, Tel: [phone], Email: [email protected]; Investor Relations: Liolios Group, Inc., Ron Both, Tel: [phone], [email protected], Renmark Financial Communications Inc., Barry Mire, Tel: [phone] or 514 939-3989, [email protected]